2022. Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s71. DOI:https://doi.org/10.25251/skin.6.supp.71.